The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.

OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies ...

Despite recent evidence of its financial turnaround, Thermo Fisher’s layoff spree will continue into 2025. | Despite recent ...

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

Researchers have developed a gene therapy that may provide a long-term treatment for hypophosphatasia. Unlike current ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by injection three-to-six times each week.

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that must be delivered by ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.